{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-151999","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2026-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.829103+00:00","generated_at":"2026-05-15T06:35:52.080939+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Allogene's cema-cel shows 41.6% MRD clearance advantage in ALPHA3 Phase 2 interim","bullets":["58.3% (7/12) of cema-cel patients achieved MRD negativity vs 16.7% (2/12) in observation arm.","No CRS, ICANS, or GvHD reported; 10 of 12 cema-cel patients managed fully outpatient.","Plasma ctDNA decreased 97.7% median in cema-cel arm vs 26.6% increase in observation at Day 45.","Cema-cel arm had more aggressive disease (100% stage III-IV, 41.7% IPI 4-5) than observation.","ALPHA3 targets ~220 patients; enrollment complete by end 2027; interim EFS mid-2027, primary mid-2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-151999","json":"https://secwatch.observer/filing/0001193125-26-151999.json","markdown":"https://secwatch.observer/filing/0001193125-26-151999.md","text":"https://secwatch.observer/filing/0001193125-26-151999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526151999/0001193125-26-151999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526151999/d49895d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:35:52.080939+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}